These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29474007)

  • 1. Predictors and Moderators of Relapse in Children and Adolescents With Major Depressive Disorder.
    Kennard BD; Mayes TL; Chahal Z; Nakonezny PA; Moorehead A; Emslie GJ
    J Clin Psychiatry; 2018; 79(2):. PubMed ID: 29474007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continued Effectiveness of Relapse Prevention Cognitive-Behavioral Therapy Following Fluoxetine Treatment in Youth With Major Depressive Disorder.
    Emslie GJ; Kennard BD; Mayes TL; Nakonezny PA; Moore J; Jones JM; Foxwell AA; King J
    J Am Acad Child Adolesc Psychiatry; 2015 Dec; 54(12):991-8. PubMed ID: 26598474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine.
    Yang H; Chuzi S; Sinicropi-Yao L; Johnson D; Chen Y; Clain A; Baer L; McGrath PJ; Stewart JW; Fava M; Papakostas GI
    Eur Arch Psychiatry Clin Neurosci; 2010 Mar; 260(2):145-50. PubMed ID: 19572158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insomnia moderates outcome of serotonin-selective reuptake inhibitor treatment in depressed youth.
    Emslie GJ; Kennard BD; Mayes TL; Nakonezny PA; Zhu L; Tao R; Hughes C; Croarkin P
    J Child Adolesc Psychopharmacol; 2012 Feb; 22(1):21-8. PubMed ID: 22257126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study.
    Kornstein SG; Pedersen RD; Holland PJ; Nemeroff CB; Rothschild AJ; Thase ME; Trivedi MH; Ninan PT; Keller MB
    J Clin Psychiatry; 2014 Jan; 75(1):62-8. PubMed ID: 24345717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS).
    Curry J; Rohde P; Simons A; Silva S; Vitiello B; Kratochvil C; Reinecke M; Feeny N; Wells K; Pathak S; Weller E; Rosenberg D; Kennard B; Robins M; Ginsburg G; March J;
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1427-39. PubMed ID: 17135988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents.
    Emslie GJ; Kennard BD; Mayes TL; Nightingale-Teresi J; Carmody T; Hughes CW; Rush AJ; Tao R; Rintelmann JW
    Am J Psychiatry; 2008 Apr; 165(4):459-67. PubMed ID: 18281410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression.
    McGrath PJ; Stewart JW; Petkova E; Quitkin FM; Amsterdam JD; Fawcett J; Reimherr FW; Rosenbaum JF; Beasley CM
    J Clin Psychiatry; 2000 Jul; 61(7):518-24. PubMed ID: 10937611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.
    Goodyer IM; Dubicka B; Wilkinson P; Kelvin R; Roberts C; Byford S; Breen S; Ford C; Barrett B; Leech A; Rothwell J; White L; Harrington R
    Health Technol Assess; 2008 May; 12(14):iii-iv, ix-60. PubMed ID: 18462573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.
    March JS; Silva S; Petrycki S; Curry J; Wells K; Fairbank J; Burns B; Domino M; McNulty S; Vitiello B; Severe J
    Arch Gen Psychiatry; 2007 Oct; 64(10):1132-43. PubMed ID: 17909125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS).
    Kennard B; Silva S; Vitiello B; Curry J; Kratochvil C; Simons A; Hughes J; Feeny N; Weller E; Sweeney M; Reinecke M; Pathak S; Ginsburg G; Emslie G; March J;
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1404-11. PubMed ID: 17135985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
    Fava M; Schaefer K; Huang H; Wilson A; Iosifescu DV; Mischoulon D; Wessel TC
    J Clin Psychiatry; 2011 Apr; 72(4):473-9. PubMed ID: 21208574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ongoing or re-emerging subjective insomnia symptoms after full/partial remission or recovery of major depressive disorder mainly with the selective serotonin reuptake inhibitors and risk of relapse or recurrence: a 52-week follow-up study.
    Gulec M; Selvi Y; Boysan M; Aydin A; Besiroglu L; Agargun MY
    J Affect Disord; 2011 Nov; 134(1-3):257-65. PubMed ID: 21684011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuation cognitive-behavioural therapy maintains attributional style improvement in depressed patients responding acutely to fluoxetine.
    Petersen T; Harley R; Papakostas GI; Montoya HD; Fava M; Alpert JE
    Psychol Med; 2004 Apr; 34(3):555-61. PubMed ID: 15259840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptom clusters in adolescent depression and differential response to treatment: a secondary analysis of the Treatment for Adolescents with Depression Study randomised trial.
    Bondar J; Caye A; Chekroud AM; Kieling C
    Lancet Psychiatry; 2020 Apr; 7(4):337-343. PubMed ID: 32199509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment.
    Iosifescu DV; Nierenberg AA; Alpert JE; Papakostas GI; Perlis RH; Sonawalla S; Fava M
    Psychosomatics; 2004; 45(5):419-25. PubMed ID: 15345787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study.
    Asnis GM; Bose A; Gommoll CP; Chen C; Greenberg WM
    J Clin Psychiatry; 2013 Mar; 74(3):242-8. PubMed ID: 23561229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression.
    Krystal A; Fava M; Rubens R; Wessel T; Caron J; Wilson P; Roth T; McCall WV
    J Clin Sleep Med; 2007 Feb; 3(1):48-55. PubMed ID: 17557453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early prediction of acute antidepressant treatment response and remission in pediatric major depressive disorder.
    Tao R; Emslie G; Mayes T; Nakonezny P; Kennard B; Hughes C
    J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):71-8. PubMed ID: 19057412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico.
    Tamayo JM; Sutton VK; Mattei MA; Diaz B; Jamal HH; Vieta E; Zarate CA; Fumero I; Tohen M
    J Clin Psychopharmacol; 2009 Aug; 29(4):358-61. PubMed ID: 19593175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.